BACKGROUND: High-density lipoprotein (HDL) protects against arterial atherothrombosis, but it is unknown whether it protects against recurrent @entity1211 . METHODS AND RESULTS: We studied 772 @entity1 after a first @entity1211 (average follow-up 48 months) and recorded the end point of symptomatic recurrent @entity1211 , which developed in 100 of the 772 @entity1 . The relationship between plasma lipoprotein parameters and recurrence was evaluated. Plasma apolipoproteins AI and B were measured by immunoassays for all subjects. Compared with those without recurrence, @entity1 with recurrence had lower mean (+/-SD) levels of apolipoprotein AI (1.12+/-0.22 versus 1.23+/-0.27 mg/mL, P<0.001) but similar apolipoprotein B levels. The relative risk of recurrence was 0.87 (95% CI, 0.80 to 0.94) for each increase of 0.1 mg/mL in plasma apolipoprotein AI. Compared with @entity1 with apolipoprotein AI levels in the lowest tertile (<1.07 mg/mL), the relative risk of recurrence was 0.46 (95% CI, 0.27 to 0.77) for the highest-tertile @entity1 (apolipoprotein AI >1.30 mg/mL) and 0.78 (95% CI, 0.50 to 1.22) for midtertile @entity1 (apolipoprotein AI of 1.07 to 1.30 mg/mL). Using nuclear magnetic resonance, we determined the levels of 10 major lipoprotein subclasses and HDL @entity165 for 71 @entity1 with recurrence and 142 matched @entity1 without recurrence. We found a strong trend for association between recurrence and low levels of HDL particles and HDL @entity165 . CONCLUSIONS: @entity1 with high levels of apolipoprotein AI and HDL have a decreased risk of recurrent @entity1211 .

High-density lipoprotein and the risk of recurrent XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity1211 :: ('MESH:D054556', 'Disease') :: ['spontaneous venous thromboembolism', 'venous thromboembolism'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']
@entity1211 :: (MESH:D054556,Disease) :: ['venous thromboembolism']
